1 |
Gidal BE, Sorkness CA, McGill KA, et al., Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995; 17: 33-38.
DOI
ScienceOn
|
2 |
Shah J, Fratis A, Ellis D, et al., Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J Clin Pharmacol 1990; 30: 733-736.
DOI
|
3 |
Qian M, Gallo JM. High-perfomance liquid chromatographic determinination of the calcium channel blocker nimodipine in monkey plasma. J Chromatogr 1992; 578: 316-320.
DOI
|
4 |
Choi JS, Burm JP. Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, flavonoid, in rabbits. Arch Pharm Res 2006; 29: 333-338.
과학기술학회마을
DOI
|
5 |
Piao YJ, Choi JS. Effects of fluvastatin on the pharmacokinetics of diltiazem and its metabolite in rats. Yakhak Hoeji 2006; 50: 118-123.
|
6 |
Choi DH, Lee IG, Choi JS. Pharmacokinetic interaction between fluvastatin and nicardipine. Kor J Clin Pharm 2007; 17: 65-69.
|
7 |
Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutics efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262.
DOI
ScienceOn
|
8 |
Gent M, Blakely JA, Easton JD, et al., The Canadian American ticlopidine study(CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
|
9 |
Janzon L, Bergqvist D, Boberg J, et al., Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301-308.
DOI
ScienceOn
|
10 |
Hass Wk, Easton JD, Adams HP, et al., A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Eng J Med 1989; 321: 501-507.
DOI
ScienceOn
|
11 |
Haynes RB, Sandler RS, Larson EB, et al., A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1998; 152: 1376-1380.
|
12 |
Ito MK, Smith AR, Lee ML. Ticlopidine: a new platelet aggregation inhibitors. Clin Pharm 1992; 11: 603-617.
|
13 |
Verhaeghe R. Prophylactic antiplatelet therapy in peripheral arterial disease. Drugs 1991; 42: 51-57.
|
14 |
Solomon DH, Hart RG. Antithrombotic therapies for stroke prevention. Cur Opin Neurol 1994; 7: 48-53.
DOI
ScienceOn
|
15 |
Buur T, Larsson R, Berglund U, et al., Pharmocokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J Clin Pharmacol 1997; 37: 108-115.
DOI
ScienceOn
|
16 |
Ko JW, Desta Z, Soukhova NV, et al., In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C9 and CYP2D6. Br J Clin Pharmacol 2000; 49: 343-351.
|
17 |
Maruhn D, Siefert HM, Weber H, et al., Pharmacokinetics of nimodipine. I. communication: absorption, concentration in plasma and excretion after single administration of [ ] nimodipine in rat, dog and monkey. Arzneimittelforschung 1985; 35: 1781-1786.
|
18 |
Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc. Drugs Ther 1997; 10: 869-872.
DOI
ScienceOn
|
19 |
Epstein M, Loutzenhister RD. Effects of calcium antagonists on renal hemodynamics. Am J Kidney Dis 1990; 16: 10-14.
|
20 |
Kazda S, Garthoff B, Krause HP, et al., Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung 1982; 32: 331-338.
|
21 |
Suwelack D, Weber H, Maruhn D. Pharmacokinetics of nimodipine, II. communication: absorption, concentration in plasma and excretion after single administration of [ ] nimodipine in rat, dog and monkey. Arzneimittelforschung 1985; 35: 1787-1794.
|
22 |
Ramsch KD, Ahr G, Tettenborn D, et al., Overview on pharmacokinetics of nimodipine in healthy volunteer and in patients with subarachnoid hemorrhage. Neurochirurgia 1985; 28: 74-78.
|
23 |
Scherling D, Buhner K, Krause HP, et al., Biotransformation of nimodipine in rat, dog and monkey. Arzneimittelforschung 1991; 41: 392-398.
|
24 |
Guengerich FP, Brian WR, Iwasaki M, et al., Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrom P-450IIIA4. J Med Chem 1991; 34: 1834-1844.
|
25 |
Fuhr U, Maier-Bruggemann A, Blume H, et al., Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998; 36: 126-132.
|
26 |
Zhang L, Liu XD, Xie L, et al., P-glycoprotein restricted transport of nimodipine across blood-brain barrier. Acta Pharmacol Sin 2003; 24: 903-906.
|
27 |
Mc Donnell CG, Shorten G, Van Pelt FN. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia 2005; 60: 747-753.
DOI
ScienceOn
|